%PDF-1.5% 642 0 objendobj 648 0 obj/Filter/FlateDecode/ID[]/Index[642 17]/Info 641 0 R/Length 53/Prev 138690/Root 643 0 R/Size 659/Type/XRef/W[1 2 1]stream hbbd“b`z$o@$Þ…1012 Y{
Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling
%PDF-1.5% 375 0 objendobj 389 0 obj/Filter/FlateDecode/ID[]/Index[375 27]/Info 374 0 R/Length 74/Prev 92811/Root 376 0 R/Size 402/Type/XRef/W[1 2 1]stream hbbd“b`z$; z H0$@XPÙ€,FÒˆ
Bioanalytical Method Validation [Revised Final]
%PDF-1.5% 165 0 objendobj 171 0 obj/Filter/FlateDecode/ID[]/Index[165 19]/Info 164 0 R/Length 52/Prev 124878/Root 166 0 R/Size 184/Type/XRef/W[1 2 1]stream hbbd“b` Hl@UF#iFo
Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application
%PDF-1.5% 1297 0 objendobj 1303 0 obj/Filter/FlateDecode/ID[]/Index[1297 20]/Info 1296 0 R/Length 53/Prev 124418/Root 1298 0 R/Size 1317/Type/XRef/W[1 2 1]stream hbbd“b`6 H|lǵL,F20
Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations
%PDF-1.5% 146 0 objendobj 153 0 obj/Filter/FlateDecode/ID[]/Index[146 20]/Info 145 0 R/Length 56/Prev 169540/Root 147 0 R/Size 166/Type/XRef/W[1 2 1]stream hbbd“b`6!@Ľ$ؾ
Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2015
%PDF-1.6% 105 0 objstream hÔ—[o:9U-Jma: U}ݨj7gfb;N6Y`@o^yÄf2%wLXx+]2^k`p@0Y*^,^?e4zϬXWWÕ¾^2/qL/EoSUoeƈUÝ©diŪz3v^^nÞiHD@{.uY÷Cj]wsv]-%MÛ‡z[W+ed˲xVbYYÜ´ßžkÅ”wsJN7}al6fs7}SO’Xкtnw_j+%yIPRJfNNPIer’Ó$űe/0eɬPdql8OIJǨJu]k3CɃlQ% g|Ø…q’HTf:J*l
Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment
%PDF-1.5% 99 0 objendobj 105 0 obj/Filter/FlateDecode/ID[]/Index[99 17]/Info 98 0 R/Length 52/Prev 80125/Root 100 0 R/Size 116/Type/XRef/W[1 2 1]stream hbbd“b`:$C+`v@;#’#1Æ”
Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment
%PDF-1.6% 141 0 objendobj 148 0 obj/Filter/FlateDecode/ID[]/Index[141 20]/Info 140 0 R/Length 55/Prev 259003/Root 142 0 R/Size 161/Type/XRef/W[1 2 1]stream hbbd“b`^$@3{HM
Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment
%PDF-1.5% 203 0 objendobj 210 0 obj/Filter/FlateDecode/ID[]/Index[203 20]/Info 202 0 R/Length 57/Prev 195825/Root 204 0 R/Size 223/Type/XRef/W[1 2 1]stream hbbd“b`@HÓ€D Q-RH@
New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products
%PDF-1.5% 455 0 objendobj 461 0 obj/Filter/FlateDecode/ID[]/Index[455 15]/Info 454 0 R/Length 53/Prev 90230/Root 456 0 R/Size 470/Type/XRef/W[1 2 1]stream hbbd“b` $W@H